本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Enlivex Therapeutics Ltd.

1.04
-0.0100-0.95%
盘后1.03-0.0100-0.96%19:26 EDT
成交量:3.86万
成交额:4.13万
市值:2,459.70万
市盈率:-1.42
高:1.07
开:1.06
低:1.03
收:1.05
数据加载中...
2020/01/31

[修订]年度报告

[Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/01/23

[修订]年度报告

[Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2019/11/14

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/11/04

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/10/24

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/09/30

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/09/09

超过5%披露

[Amend] Statement of acquisition of beneficial ownership by individuals
2019/09/09

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/08/19

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/07/26

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/07/16

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/07/05

SEC问询函

[Cover]Correspondence
2019/06/27

超过5%披露

Statement of acquisition of beneficial ownership by individuals
2019/06/26

超过5%披露

Statement of acquisition of beneficial ownership by individuals
2019/06/26

超过5%披露

Statement of acquisition of beneficial ownership by individuals
2019/06/19

SEC问询函

[Cover]Correspondence
2019/06/19

超过5%披露

Statement of acquisition of beneficial ownership by individuals
2019/05/31

超过5%披露

General statement of acquisition of beneficial ownership
2019/05/20

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/04/30

年度报告

Annual and transition report of foreign private issuers [Sections 13 or 15(d)]